Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?

Frank J Ward, Lekh N Dahal, Rahul C Khanolkar, Sucharita P Shankar, Robert N Barker

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

CTLA-4 is an inhibitory protein that contributes to immune homeostasis and tolerance, a role that has led to its exploitation as a therapeutic in several clinical settings including cancer and autoimmune disease. Development of CTLA-4 therapies focused largely on the full-length receptor isoform but other CTLA-4 isoforms are also expressed, including a secretable form of CTLA-4 (soluble CTLA-4 [sCTLA-4]). The contribution of sCTLA-4 to immune regulation has been less well studied, primarily because it was identified some years after the original description of CTLA-4. Here, we examine how sCTLA-4 might contribute to immune regulation and ask whether it might be a biomarker to inform current CTLA-4 therapies or represent a novel CTLA-4 target for future therapeutics.

Original languageEnglish
Pages (from-to)1073-1084
Number of pages12
JournalImmunotherapy
Volume6
Issue number10
DOIs
Publication statusPublished - Oct 2014

Fingerprint Dive into the research topics of 'Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?'. Together they form a unique fingerprint.

  • Cite this